Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab + nimotuzumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2100054151Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Dec 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, nimotuzumab, carboplatin and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoints: Pathological complete remission rate and Major pathological remission rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
camrelizumabnimotuzumabcarboplatinpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100054151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054151.